Skip to main content

Fate Therapeutics, Inc.

corporate_fare Company Profile

Fate Therapeutics, Inc.

FATE·NASDAQ·Life Sciences·CIK 0001434316

We are a clinical-stage biopharmaceutical company focused on developing off-the-shelf cellular immunotherapies. Our therapeutic approach, called cellular programming, involves creating and engineering human induced pluripotent stem cells (iPSCs) to include synthetic controls of cell function. After engineering, we generate a clonal master iPSC line, which serves as a renewable source for manufacturing cell therapies. This process directs the iPSC line to produce cell therapy product candidates with uniform composition. We believe our proprietary clonal master iPSC lines can mass produce multiplexed-engineered cellular immunotherapies that are off-the-shelf and on-demand, and can be administered alone or with standard-of-care therapies. Using our iPSC product platform, we are developing off-the-shelf, multiplexed-engineered T-cell and natural killer (NK) cell product candidates. These candidates are designed to incorporate novel synthetic controls of cell function to enhance their therapeutic capacity and deliver multiple therapeutic mechanisms to patients. Our pipeline includes iPSC-derived, chimeric antigen receptor (CAR)-targeted T-cell and NK cell product candidates currently under development. Human cells as therapeutic entities have potential for severe, life-threatening diseases. CAR T-cell therapy, a form of cell therapy, has been approved by the United States Food and Drug Administration (FDA) for indications such as relapsed/refractory B-cell malignancies and relapsed/refractory multiple myeloma, and has shown use in autoimmune diseases including systemic lupus erythematosus, idiopathic inflammatory myositis, systemic sclerosis, and myasthenia gravis.

Fate Therapeutics, Inc. (NASDAQ:FATE) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 12 items for FATE at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 12 most recent items scored 7 or higher, the top rating is 9/10, with 6 rated 8 or above. Recent SEC coverage for FATE spans 8-K, 10-Q, 10-K.

Recent high-impact activity:

  • Fate Posts $139M Cash, Mid-2028 Runway; FT819 Lupus Data Shows 100% Renal Response
  • FT819 Hits 100% Month-6 Renal Response in Lupus Nephritis Cohort
  • Fate Therapeutics Wins $15M CIRM Grant to Advance Lupus CAR-T Trial
  • Fate Therapeutics Reports Q2 2026 Results: First Patient Dosed in Pivotal Lupus Nephritis Trial, Cash Runway into 2028
  • Fate Doses First Lupus Nephritis Patient in Pivotal CAR T Trial

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$6.65M
Net Income
-$136.31M
Diluted EPS
-$1.15
Op. Cash Flow
-$106.08M
Free Cash Flow
-$112.04M
Operating Income
-$147.7M
Cash & Equivalents
$46.63M
Debt / Equity
0.00×
Net Margin
-20.51×
Shares Outstanding
115.36M sh
Source: 10-K · filed 2026-02-26 · accession 0001193125-26-073699

Short Interest & Short Volume

8.32 days to cover

FINRA reported short interest of 9,972,851 shares in FATE as of the October 30, 2026 settlement, a 6.1% decrease from the prior period — about 8.3 days to cover at its recent average daily volume. On November 20, 2026, 38.1% of FATE volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)9,972,851 shares as of October 30, 2026
Change vs prior period▼ 6.1%
Days to cover8.32 at avg daily volume of 1,199,352
Daily short volume (FINRA facilities)38.1% of 2,456,354 shares on November 20, 2026
5-day average short volume41.2%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for FATE, detected from its recent SEC filings · based on capital-structure filings through 2026-11-12.

1 recent capital raise1 shelf registration

Prospectus Supplement for $100M ATM · Illustrative Dilution at $2.17

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with F →
$0.9589 +4.34% today
52-week range · as of 2026-08-13 $0.9227 – $3.23
Market cap
$111.72M
Volume
3.7M (2.2× avg)
3-mo avg 1.7M
Live data · 2026-11-22 02:51 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed FATE - Latest Insights

FATE
Nov 05, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.07
Real-time Price: $0.9589 info
Change: -$1.11 (-54%) info
Market Cap: $111.722M info
FATE
Oct 26, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $2.13
Real-time Price: $0.9589 info
Change: -$1.17 (-55%) info
Market Cap: $111.722M info
FATE
Sep 25, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.32
Real-time Price: $0.9589 info
Change: -$1.36 (-59%) info
Market Cap: $111.722M info
FATE
Aug 13, 2026, 8:31 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.77
Real-time Price: $0.9589 info
Change: -$1.81 (-65%) info
Market Cap: $111.722M info
FATE
Aug 13, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $2.77
Real-time Price: $0.9589 info
Change: -$1.81 (-65%) info
Market Cap: $111.722M info
FATE
Jul 09, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.00
Real-time Price: $0.9589 info
Change: -$2.04 (-68%) info
Market Cap: $111.722M info
FATE
Jun 15, 2026, 4:02 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.01
Real-time Price: $0.9589 info
Change: -$1.05 (-52%) info
Market Cap: $111.722M info
FATE
May 13, 2026, 8:34 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $2.20
Real-time Price: $0.9589 info
Change: -$1.24 (-56%) info
Market Cap: $111.722M info
FATE
May 13, 2026, 8:32 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.26
Real-time Price: $0.9589 info
Change: -$1.30 (-58%) info
Market Cap: $111.722M info
FATE
May 05, 2026, 8:37 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $1.98
Real-time Price: $0.9589 info
Change: -$1.02 (-52%) info
Market Cap: $111.722M info
FATE
Feb 26, 2026, 9:07 AM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $1.47
Real-time Price: $0.9589 info
Change: -$0.5093 (-35%) info
Market Cap: $111.722M info
FATE
Feb 26, 2026, 9:04 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.48
Real-time Price: $0.9589 info
Change: -$0.5211 (-35%) info
Market Cap: $111.722M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets